Annals of Oncology 2009 20(Supplement 4):iv10-iv14; doi:10.1093/annonc/mdp114
© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
ESMO clinical recommendations |
Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
V. Kataja1,
M. Castiglione2 and
On behalf of the ESMO Guidelines Working Group*
1 Department of Oncology, Vaasa Central Hospital, Vaasa and Kuopio University, Kuopio, Finland
2 Institute of Social and Preventive Medicine (ISPM), University of Geneva, Geneva, Switzerland
* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalrecommendations@esmo.org
| The first 150 words of the full text of this article appear below. |
 |
incidence
|
|---|
In 2006 the estimated age-adjusted annual incidence of breast
cancer in the European Union (25 countries) was 110.3/100 000
and the mortality 25.0/100 000. The incidence is increasing
due to mammographic screening and aging population. The mortality
rate has decreased especially in younger age groups because
of earlier detection and improved treatment. However, breast
cancer is still the leading cause of cancer-related deaths in
European women.
 |
diagnosis
|
|---|
The diagnosis is based on the triad of clinical, radiological
and pathological examinations. Clinical examination includes
bi-manual palpation of the breasts and local regional lymph
nodes. Radiological examinations include bilateral mammography
of the breasts and ultrasound of the breasts and local regional
lymph nodes. MRI of the breasts is not a routine procedure,
but may be considered in cases involving diagnostic
. . . [Full Text of this Article]
 |
staging and risk assessment
|
|---|
 |
treatment plan
|
|---|
 |
local therapy
|
|---|
non-invasive carcinomainvasive carcinoma
 |
primary (neo-adjuvant) systemic therapy
|
|---|
 |
adjuvant systemic therapy
|
|---|
 |
endocrine therapy
|
|---|
 |
chemotherapy
|
|---|
 |
trastuzumab
|
|---|
 |
follow-up
|
|---|
 |
note
|
|---|

CiteULike
Connotea
Del.icio.us What's this?